Researchers at Oregon Health & Science University have received a five-year, $5.8 million award from the National Institute of Mental Health, part of the National Institutes of Health, to examine whether damage to the gastrointestinal tract contributes to neuroinflammation in people living with HIV. The work could eventually point toward treatments that protect brain function in people with HIV and in older adults.
The motivation comes from a pattern clinicians have noticed. Antiretroviral drugs are very effective at suppressing the virus, yet people living with HIV still show neurocognitive disorders similar to those seen with normal aging. The researchers want to determine whether there is a dynamic relationship between inflammation in the gut and in the brain. If such a link can be shown, it could open the door to therapies aimed at reducing inflammation in the brain.
The gut connection is not new territory. Scientists have long associated inflammation in the GI tract with impaired cognition, and people with inflammatory bowel disease face a higher risk of Parkinson's and Alzheimer's disease. The team's working explanation is that the initial viral infection causes lasting damage to immune cells in the gut, and that this damage persists even after the virus is held in check by antiretroviral therapy.
To test this, the project will pair nonhuman primate models with human autopsy tissue, an approach the investigators say allows them to study the interplay between gut and brain inflammation more directly. Pathologists at OHSU and infectious disease specialists at the NIH will join the effort to characterize how gut inflammation connects to brain function. Investigators have acknowledged the difficulty of this work, with one describing it as high risk but also high reward.
The longer-term goal is not to shut down the immune system but to fine-tune it. Co-lead investigator Jacob Estes noted that inflammation is part of the normal immune response to infection. The hope is that research like this could identify precise targets that limit the inflammation harming brain function while preserving the immune activity the body needs.